Melatonin, a suitable lead compound for rational drug design;La melatonine, prototype pertinent pour l'innovation therapeutique

Therapie

Volumn 53, Issue 5, 1998, Pages 429-437

  Lesieur, D ^a   Leclerc, V ^a   Chavatte, P ^a   Marot, C ^b   Renard, P ^c   Guardiola Lemaitre, B ^c  

^a Universite de Lille   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c ADIR   (France)

Author keywords

Agomelatin; Drug design; Melatonin; Melatoninergic receptors; Structure activity relationships

Indexed keywords

AGOMELATINE; MELATONIN; MELATONIN RECEPTOR; ACETAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE; CELL RECEPTOR; CELL SURFACE RECEPTOR; CYCLIC AMP; LIGAND; NAPHTHALENE DERIVATIVE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; DRUG RECEPTOR BINDING; HUMAN; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; METABOLISM; SHEEP;

ACETAMIDES; ANIMALS; BENZOFURANS; CYCLIC AMP; DRUG DESIGN; LIGANDS; MELATONIN; MODELS, MOLECULAR; NAPHTHALENES; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; SHEEP; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 0032151470     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Morgan P, Williams L, Davidson G et al. Melatonin receptors of the ovine pars tuberalis: characterization and autoradiographical localization. J Neuro Endocrinol 1989; 1: 1-4.
2. Morgan P, Barrett P, Howell E, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994; 24: 101-146.
3. Cagnacci A. Melatonin in relation to physiology in adult humans. J Pineal Res 1996; 21: 200-213.
4. Arendt J. Clinical perspectives for melatonin and its agonists. Biol psychiatry 1994; 1.
5. Maestroni G, Conti A, Reiter R. Therapeutic potential of melatonin. Series Frontiers of Hormone Research 1997; 23.
6. Di W, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med 1997; 336: 1028-1029.
7. Morgan P, Lawson W, Davidson G, Howell E. Melatonin inhibits cyclic AMP production in cultured ovine pars tuberalis cells. J Mol Endocrinol 1989; 3: R5-R8.
8. Mathé M, Gaudy F, Sicsic S et al. Synthesis of 2 amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem 1996; 39: 3089-3095.
9. 125 I] iodomelatonin binding sites. J Med Chem 1995; 38: 2050-2060.
10. Garratt P, Vonhoff S, Rowe S, Sugden D. Mapping the melatonin receptor, 2: Synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain. Bioorg Med Chem Lett 1994; 4: 1559-1564.
11. Garratt P, Travard S, Vonhoff S. Mapping the melatonin receptor, 4: Comparison of the binding affinities of a series of substituted phenylalkylamides ligands. J Med Chem 1996; 39: 1797-1805.
12. Sicsic S, Serraz I, Andrieux J et al. 3D quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study. J Med Chem 1997; 40: 739-748.
13. Stewart J. A semi-empirical molecular orbital program. J Comput Aided Mol Des 1990; 4: 1-103.
14. Cramer R, Patterson D, Bunce J. Comparative molecular field analysis (CoMFA), 1: Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988; 110: 5959-5967.
15. Gaillard P, Carrupt P, Testa B et al. Molecular lipophilicity potential, a tool in 3D QSAR. Method and applications. J Comput Aided Mol Des 1994; 8: 83-96.
16. Depreux P, Lesieur D, Ait Mansour H et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 1994; 37: 3231-3239.
17. Sugden D, Chong N, Lewis D. Structural requirements at the melatonin receptor. Brit J Pharmacol 1995; 114: 618-623.
18. Garratt P, Jones R, Roxe S, Sugden D. Mapping the melatonin receptor, 1: The 5 methoxyl group of melatonin is not an essential requirement for biological activity. Bioorg Med Chem Lett 1994; 4: 1555-1558.
19. Heward C, Hadley M. Structure-activity relationships of melatonin and related indoleamines. Life Sci 1975; 17: 1167-1178.
20. Krause D, Dubocovich M. Melatonin receptors. Annu Rev Pharmacol Toxicol 1991; 31: 549-568.
21. Ebisawa T, Karne S, Lerner M, Reppert S. Expression cloning of a high affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci USA 1994; 91: 6133-6137.
22. Reppert S, Weaver D, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 1996; 17: 100-102.